Literature DB >> 1655322

Ketoconazole and plasma and urine steroid levels in Cushing's disease.

R H Mortimer1, G R Cannell, C M Thew, J P Galligan.   

Abstract

1. Plasma and urine steroid and plasma ACTH levels were measured for 2 weeks in eight subjects (six female, two male) with Cushing's disease with each given 200 mg ketoconazole orally four times daily. 2. Treatment was associated with major falls in excretion of free cortisol and the cortisol metabolites tetrahydrocortisol, 5 alpha-tetrahydrocortisol and tetrahydrocortisone. 3. Plasma cortisol and ACTH levels did not change significantly. 4. Excretion of the androgen metabolites, androsterone, 11 beta-hydroxyandrosterone and aetiocholanolone was also reduced but there was no significant fall in plasma testosterone. Plasma levels of progesterone, 17 alpha-hydroxyprogesterone and 11 beta-deoxycortisol and excretion of pregnanediol, pregnanetriol and tetrahydrodeoxycortisol rose with treatment. 5. Analysis of steroid precursor/product ratios indicated that ketoconazole significantly inhibited 11 beta-hydroxylase and 17,20-lyase but not 17 alpha-hydroxylase in these patients with Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1655322     DOI: 10.1111/j.1440-1681.1991.tb01492.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  6 in total

Review 1.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 2.  Steroid biosynthesis inhibitors in Cushing's syndrome.

Authors:  D Engelhardt
Journal:  Clin Investig       Date:  1994-07

3.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

Review 4.  Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies.

Authors:  Maria Fleseriu; Frederic Castinetti
Journal:  Pituitary       Date:  2016-12       Impact factor: 4.107

5.  Ketoconazole- and Metyrapone-Induced Reductions on Urinary Steroid Metabolites Alter the Urinary Free Cortisol Immunoassay Reliability in Cushing Syndrome.

Authors:  Arturo Vega-Beyhart; Javier Laguna-Moreno; Daniela Díaz-Catalán; Laura Boswell; Mireia Mora; Irene Halperin; Gregori Casals; Felicia A Hanzu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-23       Impact factor: 5.555

6.  Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome.

Authors:  Eliza B Geer; Roberto Salvatori; Atanaska Elenkova; Maria Fleseriu; Rosario Pivonello; Przemyslaw Witek; Richard A Feelders; Marie Bex; Stina W Borresen; Soraya Puglisi; Beverly M K Biller; Fredric Cohen; Francesca Pecori Giraldi
Journal:  Pituitary       Date:  2020-11-20       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.